Effect of hormone replacement therapy on the susceptibility of low-density lipoprotein to oxidation among postmenopausal hypercholesterolaemic women.
The effect of sequential combined hormone replacement therapy on the susceptibility of low-density lipoprotein to oxidative modification was investigated in a double-blind, randomized placebo-controlled study. Hypercholesterolaemic, postmenopausal women were supplemented with 17 beta-oestradiol and norethisterone acetate (n = 13 subjects) or placebo capsules (n = 15 subjects) for 12 weeks. They were instructed to follow the American Heart Association step one diet. Low-density lipoprotein, isolated before and after treatment, was subjected to copper-catalysed lipid peroxidation. There were no significant differences between low-density lipoprotein from the hormone replacement therapy and placebo groups, as assessed by measuring the lag time for formation of conjugated dienes, the rate of formation and the amount of conjugated dienes formed, the amount of lipid peroxides generated, and the relative electrophoretic mobility at baseline and after treatment. Dietary records showed that the subjects were consuming similar amounts of fat and vitamins. No major differences were found in the fatty acid pattern of low-density lipoprotein from the two groups. In conclusion, the results indicated that hormone replacement therapy with 17 beta-oestradiol sequentially combined with norethisterone acetate in non-smoking, hypercholesterolaemic, postmenopausal women has no protective effect on the susceptibility of low-density lipoprotein to copper-catalysed modification in vitro.
Nenseter
M S
MS
Institute for Nutrition Research, University of Oslo, Norway.
Volden
V
V
Berg
T
T
Drevon
C A
CA
Ose
L
L
Tonstad
S
S
D000328:Adult; D004958:Estradiol / Q000097:blood / Q000627:therapeutic use; D015914:Estrogen Replacement Therapy; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood*; D008075:Lipoproteins, HDL / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood* / Q000737:chemistry / Q000378:metabolism; D008875:Middle Aged; D009640:Norethindrone / Q000627:therapeutic use; D010084:Oxidation-Reduction; D017698:Postmenopause / Q000097:blood* / Q000378:metabolism*
D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D004958:Estradiol; D009640:Norethindrone